Orencia Abatacept Injection Arthritis Application Scope:

Indicated for the treatment of:
• Moderate to severe active rheumatoid arthritis in adults
• Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
• Active psoriatic arthritis in adults

Orencia Abatacept Injection Arthritis Characteristics

Ingredients: Abatacept (recombinant fusion protein of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1)
Properties: A clear to slightly opalescent, colorless to pale yellow solution
Packaging Specification: Prefilled syringe: 125 mg/mL in 1 mL single-use prefilled syringe
• Vial for IV infusion: 250 mg lyophilized powder per vial
Storage: Store refrigerated at 2°C–8°C. Do not freeze. Protect from light.
Expiry Date: 24 months from manufacturing date (refer to packaging)
Executive Standard: YBH08272020 (for Chinese NMPA-registered product)
Approval Number: S20200043
Date of Revision: February 2024
Manufacturer: Bristol-Myers Squibb Company / Imported and distributed by appropriate licensee in China

Guidelines for the Use of Orencia Abatacept Injection

Dosage and Administration:
- Recommended Dose: 80 mg administered subcutaneously once every 4 weeks.
- Administration: Administer via subcutaneous injection using the single-dose autoinjector.
- Missed Dose: If a dose is missed, administer as soon as possible. Resume monthly dosing from the date of the most recently administered dose.
Adverse Reactions:
- Common Adverse Reactions (≥5% and >3% higher than placebo):
  - Injection site reactions (19%)
  - Decreased platelet count (12%)
  - Arthralgia (9%)
- Serious Adverse Reactions:
  - Hypersensitivity reactions, including bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias.
Contraindications:Patients with a history of serious hypersensitivity to olezarsen or any of the excipients in TRYNGOLZA.
Precautions:
- Hypersensitivity Reactions: Monitor patients for signs and symptoms. Discontinue use if reactions occur.
- Platelet Count Monitoring: Monitor platelet counts during treatment.
- Pregnancy and Lactation: Advise patients to inform their healthcare provider if they are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Orencia Abatacept Injection Interactions

• Should not be used in combination with biologic TNF inhibitors due to increased risk of serious infections
• May affect the immune response to vaccinations
• No significant interaction with methotrexate or corticosteroids observed

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.